CRANFORD, N.J., Nov. 8, 2019 /PRNewswire/ -- Citius
Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius" or the
"Company"), a specialty pharmaceutical company focused on
adjunctive cancer care and critical care drug products, today
announced that the Company has issued its October
2019 Corporate Update Letter. The Letter highlights the
progress of the Company's product candidates Mino-Lok®, Mino-Wrap™,
and Halo-Lido, along with details on its strategic goals to develop
breakthrough technologies to improve and enhance the lives of
patients.
Recent Company Highlights include:
- Closing on a recent $7 million
capital raise to advance ongoing research
- A recent modification to the primary endpoint of the pivotal
Phase III trial for Mino-Lok that substantially reduced the
required trial sample size from 700 to approximately 144 subjects,
significantly reducing the trial's expense and accelerating
its completion
- An expanded relationship with MD Anderson Cancer Center for a
worldwide license for Mino-Wrap and the preparation for a pre-IND
meeting with the FDA
- Reformulating the topical formulation (now Halo-Lido) for the
treatment of hemorrhoids based on results from an initial Phase II
study. A toxicology study will be initiated by year-end ahead
of an expanded Phase II study to start in 2020
- Other corporate initiatives that include industry events and
investor outreach
To view the Company's Corporate Update Letter in its entirety,
please visit:
https://www.citiuspharma.com/wp-content/uploads/2019/11/CTXR-ShareholderLetter-Nov2019.pdf
About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the
development and commercialization of critical care products, with a
focus on anti-infectives, cancer care, and unique prescription
products that use innovative, patented, or proprietary formulations
of previously-approved active pharmaceutical ingredients. We seek
to achieve leading market positions by providing therapeutic
products that address unmet medical needs. By using
previously approved drugs with substantial safety and efficacy
data, we seek to reduce the risks associated with pharmaceutical
product development and regulatory requirements. Citius develops
products that have intellectual property protection and competitive
advantages to existing therapeutic approaches. For more
information, please visit www.citiuspharma.com.
Safe Harbor
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
are made based on our expectations and beliefs concerning future
events impacting Citius. You can identify these statements by the
fact that they use words such as "will," "anticipate," "estimate,"
"expect," "should," and "may" and other words and terms of similar
meaning or use of future dates. Forward-looking statements are
based on management's current expectations and are subject to risks
and uncertainties that could negatively affect our business,
operating results, financial condition and stock price.
Factors that could cause actual results to differ materially from
those currently anticipated are: risks associated with conducting
our Phase 3 trial for Mino-Lok®, including completing patient
enrollment, opening study sites and achieving the required number
of catheter failure events; the estimated markets for our product
candidates and the acceptance thereof by any market; our need for
substantial additional funds; risks associated with developing
Mino-Wrap™, including that preclinical results may not be
predictive of clinical results and our ability to file an IND;
risks related to our growth strategy; our ability to identify,
acquire, close and integrate product candidates and companies
successfully and on a timely basis; risks relating to the results
of research and development activities; uncertainties relating to
preclinical and clinical testing; the early stage of products under
development; our ability to obtain, perform under and maintain
financing and strategic agreements and relationships; our ability
to attract, integrate, and retain key personnel; government
regulation; patent and intellectual property matters; competition;
as well as other risks described in our SEC filings. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in our expectations or any changes in
events, conditions or circumstances on which any such statement is
based, except as required by law.
Contact:
Andrew
Scott
Vice President - Corporate
Development
(O) 908-967-6677 x105
ascott@citiuspharma.com
View original
content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-issues-corporate-update-300954396.html
SOURCE Citius Pharmaceuticals, Inc.